A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
Latest Information Update: 23 Jan 2023
At a glance
- Drugs QLS 1128 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 23 Jan 2023 New trial record